Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H20N6O.2ClH |
Molecular Weight | 421.324 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.O=C(NC1=CC=CC(=C1)C2=NCCN2)NC3=CC=CC(=C3)C4=NCCN4
InChI
InChIKey=MLRXMTYSQKIKAK-UHFFFAOYSA-N
InChI=1S/C19H20N6O.2ClH/c26-19(24-15-5-1-3-13(11-15)17-20-7-8-21-17)25-16-6-2-4-14(12-16)18-22-9-10-23-18;;/h1-6,11-12H,7-10H2,(H,20,21)(H,22,23)(H2,24,25,26);2*1H
Molecular Formula | C19H20N6O |
Molecular Weight | 348.4017 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Imidocarb is a carbanilide derivative with antiprotozoal activity. It is usually administered as the dipropionate salt. Imidocarb is a drug sold under the brand name Imizol and is used to treat canine ehrlichiosis. wo mechanisms of action have been proposed:
As the effect of imidocarb on Trypanosoma brucei is antagonized by excess polyamines, it is has been suggested that imidocarb interferes with their production and/or use. Imidocarb blocks the entry of inositol into erythrocytes containing Babesia, resulting in starvation of the parasite. It is generally accepted in that imidocarb has anticholinesterase activity.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4768 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27301742 |
|||
Target ID: CHEMBL2966 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27301742 |
|||
Target ID: CHEMBL220 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20053484 |
590.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Imizol Approved UseFor the treatment of babesiosis in dogs with clinical signs and/or demonstrated Babesia organisms in the blood. Launch Date1997 |
|||
Curative | IMIDOCARB Approved UseFor treatment of babesiosis in cattle and horses Launch Date2001 |
PubMed
Title | Date | PubMed |
---|---|---|
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. | 1992 Sep |
|
Residual effect of antibabesial drugs on the live redwater blood vaccines. | 2002 Oct |
|
Evaluation of certain veterinary drug residues in food. | 2003 |
|
In-vivo therapeutic efficacy trial with artemisinin derivative, buparvaquone and imidocarb dipropionate against Babesia equi infection in donkeys. | 2003 Nov |
|
Concurrent bartonellosis and babesiosis in a dog with persistent thrombocytopenia. | 2003 Nov 1 |
|
Imidocarb, a potent anti-protozoan drug, up-regulates interleukin-10 production by murine macrophages. | 2003 Sep 19 |
|
[A literature review of equine piroplasmosis after an episode of acute babesiosis in a Dutch Standardbred foal after a stay in Normandy]. | 2005 Dec 1 |
|
Autochthonous canine babesiosis in The Netherlands. | 2005 Jul 15 |
|
Identification of anti-babesial activity for four ethnoveterinary plants in vitro. | 2005 Jun 10 |
|
Clinical and clinicopathological changes in 6 healthy ponies following intramuscular administration of multiple doses of imidocarb dipropionate. | 2005 Mar |
|
Effective imidocarb dipropionate therapy for Babesia shortti in falcons. | 2006 Feb 18 |
|
Pharmacokinetics and mammary elimination of imidocarb in sheep and goats. | 2006 Jul |
|
Failure of imidocarb dipropionate to clear experimentally induced Ehrlichia canis infection in dogs. | 2006 Jul-Aug |
|
Flow cytometric evaluation of selected antimicrobial efficacy for clearance of Anaplasma marginale in short-term erythrocyte cultures. | 2006 Jun |
|
Effect of imidocarb and levamisole on the experimental infection of BALB/c mice by Leishmania (Leishmania) amazonensis. | 2006 Jun 30 |
|
Clinicopathological changes and effect of imidocarb therapy in dogs experimentally infected with Babesia canis. | 2006 Mar |
|
Chemotherapy against babesiosis. | 2006 May 31 |
|
Clinical manifestations of canine babesiosis in Hungary (63 cases). | 2006 Sep |
|
Comparison of the efficacy of enrofloxacin, imidocarb, and oxytetracycline for clearance of persistent Anaplasma marginale infections in cattle. | 2006 Winter |
|
Pharmacokinetics and bioavailability of imidocarb dipropionate in swine. | 2007 Aug |
|
Histological and ultrastructural studies of renal lesions in Babesia canis infected dogs treated with imidocarb. | 2007 Dec |
|
Molecular characterisation of Babesia gibsoni infection from a pit-bull terrier pup recently imported into South Africa. | 2007 Mar |
|
Evidence of an acute phase response in dogs naturally infected with Babesia canis. | 2007 Mar 31 |
|
Therapeutic and prophylactic efficacy of imidocarb dipropionate on experimental Babesia ovis infection of lambs. | 2007 Oct 21 |
|
[Dogs babesiosis--still actually problem]. | 2008 |
|
Canine vector-borne diseases in Brazil. | 2008 Aug 8 |
|
Treatment of Mycoplasma wenyonii infection in cows with imidocarb dipropionate injection-acupuncture. | 2008 Dec |
|
Repeated high dose imidocarb dipropionate treatment did not eliminate Babesia caballi from naturally infected horses as determined by PCR-reverse line blot hybridization. | 2008 Feb 14 |
|
The clinical course of babesiosis in 76 dogs infected with protozoan parasites Babesia canis canis. | 2009 |
|
Diagnosis and treatment of Babesia odocoilei in captive reindeer (Rangifer tarandus tarandus) and recognition of three novel host species. | 2009 Mar |
|
Babesia and its hosts: adaptation to long-lasting interactions as a way to achieve efficient transmission. | 2009 Mar-Apr |
|
Failure of imidocarb dipropionate to eliminate Hepatozoon canis in naturally infected dogs based on parasitological and molecular evaluation methods. | 2010 Aug 4 |
|
First case of babesiosis caused by Babesia canis canis in a dog from Norway. | 2010 Aug 4 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/vet/imizol.html
Use intramuscularly or subcutaneously at a rate of 6.6 mg/kg (3 mg/lb) body weight. Repeat the dose in two (2) weeks, for a total of two (2) treatments.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2242963
The concentration of Imidocarb causing 50% inhibition of [3H]hypoxanthine incorporation (ID50 value) by Babesia bovis (Lismore and Samford isolates) cultured in vitro for Imidocarb was determined to be 3 ng/ml (8.6 nM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:21:23 GMT 2023
by
admin
on
Fri Dec 15 15:21:23 GMT 2023
|
Record UNII |
KCC1V76AH8
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C277
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID30201240
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | |||
|
300000023746
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | |||
|
m6226
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | Merck Index | ||
|
C76422
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | |||
|
CHEMBL427342
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | |||
|
226-179-7
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | |||
|
51189
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | |||
|
21388
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | |||
|
KCC1V76AH8
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY | |||
|
5318-76-3
Created by
admin on Fri Dec 15 15:21:23 GMT 2023 , Edited by admin on Fri Dec 15 15:21:23 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |